Is It Time To Revisit TransMedics Group (TMDX) After Its Strong Three Year Run?
- If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues.
- The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%.
- Recent headlines around TransMedics Group have continued to focus on its position in the organ transplant technology space and investor interest in medical equipment companies more broadly. This context has kept attention on how much future potential may already be reflected in the current share price.
- On Simply Wall St's valuation checklist, TransMedics Group currently scores 5 out of 6. The next sections break down what different valuation methods are saying about the stock and finish with a framework that can help you make sense of all those numbers in a more complete way.
Approach 1: TransMedics Group Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and discounting them back to today’s value. For TransMedics Group, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $.
The latest twelve month free cash flow is about $32.7 million. Analyst input feeds into near term projections, then Simply Wall St extrapolates further out. By 2028, free cash flow is projected at $220.0 million, with a path of annual estimates running through 2035 that are discounted back to present value.
Aggregating these discounted cash flows gives an estimated intrinsic value of about $181.64 per share. Compared with the recent share price of around $110.93, the model indicates that TransMedics Group may be trading at roughly a 38.9% discount to this intrinsic estimate on this DCF view.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests TransMedics Group is undervalued by 38.9%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.
Approach 2: TransMedics Group Price vs Earnings
For profitable companies, the P/E ratio is a useful shorthand because it links what you pay per share to the earnings that each share generates. Higher growth and lower perceived risk usually support a higher “normal” P/E, while slower growth or greater uncertainty tend to justify a lower multiple.
TransMedics Group currently trades on a P/E of about 20.1x. That sits below the Medical Equipment industry average of roughly 25.1x and also below the peer group average of around 44.4x. On the surface, that might suggest the market is applying a more cautious earnings multiple than it does to many other medical equipment names.
Simply Wall St’s Fair Ratio for TransMedics Group is 19.6x. This is a proprietary estimate of what the P/E could be given factors such as the company’s earnings growth profile, industry, profit margins, market cap and specific risks. Because it blends these company level inputs, the Fair Ratio can be more informative than a simple comparison with industry or peer averages that do not adjust for differences in growth or risk.
With the current P/E of 20.1x sitting very close to the Fair Ratio of 19.6x, the shares look priced at about the level the model would suggest.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your TransMedics Group Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring that to life by letting you attach a simple story about TransMedics Group to the numbers you care about, such as your own view of fair value and the paths for future revenue, earnings and margins.
A Narrative connects three things: what you think is happening with the business, how that flows into a forecast, and what share price that set of assumptions may justify.
On Simply Wall St, Narratives are available on the Community page and are designed to be easy to use, so you can pick a view that fits you rather than trying to reverse engineer every line of a model.
Once you have a Narrative, you can compare its Fair Value to the current price to help decide whether the stock looks expensive, cheap, or somewhere in between for that particular story.
Because Narratives update automatically when new earnings, guidance or news are added to the platform, your chosen story stays aligned with the latest information instead of going stale on a spreadsheet.
For TransMedics Group, one Narrative currently anchors on a higher Fair Value of US$190.00 while another uses a lower Fair Value of US$114.00. This shows how different investors, using the same company, can reach very different conclusions based on the story they believe is more likely.
Do you think there's more to the story for TransMedics Group? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com